Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$146.41M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 31, 2025 | $75,128,000 | February 24, 2026 | 10-K ↗ |
| January 1, 2024 – December 31, 2024 | $28,833,000 | February 24, 2026 | 10-K ↗ |
| January 1, 2023 – December 31, 2023 | $38,025,000 | February 24, 2026 | 10-K ↗ |
| January 1, 2022 – December 31, 2022 | $485,424,000 | February 27, 2025 | 10-K ↗ |
| January 1, 2021 – December 31, 2021 | $375,203,000 | February 20, 2024 | 10-K ↗ |
| January 1, 2020 – December 31, 2020 | $233,155,000 | February 21, 2023 | 10-K ↗ |
| January 1, 2019 – December 31, 2019 | $11,612,000 | February 25, 2022 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 8, 2026
Response SHA-256: b2742f18d0249f1de2284e7f5a68039ab8f6da582c31075b440162e94660cf3a
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.